NCPA to Congress: Scrutinize PBM Corporations as Part of Drug Cost Review
Increased transparency into the business practices and potential conflicts of interests of pharmacy benefit manager (PBM) corporations could provide tangible benefits to payers, patients and pharmacists, the National Community Pharmacists Association (NCPA) said in comments submitted to the House Committee on Oversight and Government Reform, which held a hearing today on the prescription drug market. "The current business climate seems to be one in which market power is incre